Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention

YAR Mahaman, KS Embaye, F Huang, L Li, F Zhu… - Ageing research …, 2022 - Elsevier
Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

Role of oxidative damage in alzheimer's disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery

FR Buccellato, M D'Anca, C Fenoglio, E Scarpini… - Antioxidants, 2021 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder accounting for over 50% of all
dementia patients and representing a leading cause of death worldwide for the global …

Microglial REV-ERBα regulates inflammation and lipid droplet formation to drive tauopathy in male mice

J Lee, JM Dimitry, JH Song, M Son… - Nature …, 2023 - nature.com
Alzheimer's disease, the most common age-related neurodegenerative disease, is
characterized by tau aggregation and associated with disrupted circadian rhythms and …

Cholesterol metabolism in aging and age-related disorders

G Saher - Annual Review of Neuroscience, 2023 - annualreviews.org
All mammalian cell membranes contain cholesterol to maintain membrane integrity. The
transport of this hydrophobic lipid is mediated by lipoproteins. Cholesterol is especially …

Integrative metabolomics science in Alzheimer's disease: relevance and future perspectives

S Lista, R González-Domínguez, S López-Ortiz… - Ageing Research …, 2023 - Elsevier
Alzheimer's disease (AD) is determined by various pathophysiological mechanisms starting
10–25 years before the onset of clinical symptoms. As multiple functionally interconnected …

Symptomatic and disease-modifying therapy pipeline for Alzheimer's disease: Towards a personalized polypharmacology patient-centered approach

X Morató, V Pytel, S Jofresa, A Ruiz… - International Journal of …, 2022 - mdpi.com
Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development

H Ahmed, Y Wang, WJ Griffiths, AI Levey, I Pikuleva… - Brain, 2024 - academic.oup.com
Cholesterol homeostasis is impaired in Alzheimer's disease; however, attempts to modulate
brain cholesterol biology have not translated into tangible clinical benefits for patients to …

Status of metabolomic measurement for insights in Alzheimer's disease progression—What is missing?

C Yin, AC Harms, T Hankemeier, A Kindt… - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the
progressive loss of memory and other cognitive functions. As there is still no cure for AD, the …

Systematic review of brain and blood lipidomics in Alzheimer's disease mouse models

L Ferré-González, A Lloret, C Cháfer-Pericás - Progress in Lipid Research, 2023 - Elsevier
Alzheimer's disease (AD) diagnosis is based on invasive and expensive biomarkers.
Regarding AD pathophysiological mechanisms, there is evidence of a link between AD and …

Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment

JCS Chaves, SJ Dando, AR White, LE Oikari - Biochimica et Biophysica …, 2024 - Elsevier
The blood-brain-barrier (BBB) has a major function in maintaining brain homeostasis by
regulating the entry of molecules from the blood to the brain. Key players in BBB function are …